Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice

Area of Science:

• Oncology
• Translational Medicine
• Pharmacology

Background:

• Metastatic renal cell cancer (mRCC) treatment options were historically limited.
• Advances in understanding RCC molecular pathways have led to new targeted therapies.
• Vascular endothelial growth factor (VEGF) and mTOR inhibitors are established treatment classes for mRCC.

Purpose of the Study:

• To address the lack of predictive biomarkers in mRCC.
• To establish an optimal sequence for targeted therapies in mRCC.
• To develop a treatment algorithm for first- and second-line mRCC therapy.

Main Methods:

• Review of current guidelines and phase III trial data.
• Discussion among a German RCC expert panel.
• Development of a treatment algorithm based on clinical criteria.

Main Results:

• Sequential use of targeted therapies is standard in mRCC.
• The optimal sequence of available agents remains undetermined.
• A German expert panel proposed an algorithm for first- and second-line mRCC treatment.

Conclusions:

• Targeted therapies have significantly improved mRCC treatment landscape.
• Further research is needed to identify predictive biomarkers for personalized treatment.
• The developed algorithm provides a clinical framework for sequential mRCC therapy.